Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Interest & Investment Income of $4.8 million for Q1 2026, up 5.57% year-over-year from $4.5 million in Q1 2025, and up 19.1% quarter-over-quarter from $4.0 million in Q4 2025.
Powered by 
Analysis
Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Interest & Investment Income for 7 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 5.57% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $16.5 million (up 18.93% YoY), while the FY2025 annual figure was $16.2 million, up 27.93% from the prior year.
- Interest & Investment Income rose to $4.8 million in Q1 2026 per OLMA's latest filing, from $4.0 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.8 million in Q1 2026 and bottomed at $218000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 792.66% — and 2024, when it slipped 7.24%.
- Olema Pharmaceuticals' Interest & Investment Income stood at $973000.0 in 2022, then soared by 264.95% to $3.6 million in 2023, then slipped by 7.24% to $3.3 million in 2024, then gained by 21.74% to $4.0 million in 2025, then advanced by 19.1% to $4.8 million in 2026.
- Business Quant data shows OLMA's Interest & Investment Income at $4.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | 4.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.51 Mn |
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 4.01 Mn |
| Sep 30, 2025 | 3.65 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.52 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 973,000.00 |
| Sep 30, 2022 | 622,000.00 |
| Jun 30, 2022 | 415,000.00 |
| Mar 31, 2022 | 218,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Sep 30, 2021 | 105,000.00 |